A Phase 1 interventional study of vorinostat and Gemcitabine in Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-04.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Carcinoma, Non-Small-Cell Lung.
Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2007, is one of 11 in phase 1, and was the 6th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →None of the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 9 · Phase 3 1
First in 2001; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is close to the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 21 across the 19 interventional studies. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc: 14 open now, 26 under way, 18 of them phase 3. Of 65 finished, 49 (75%) have results posted.
Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 65th largest by enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2007, is one of 19 in phase 1, and was the 10th registered.
Merck & Co., Inc’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 91 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: vorinostat · Drug: Gemcitabine · Drug: Platinum-based agent
Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days
Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle
Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
Number of Participants With Dose-limiting Toxicities (DLT) Due to Vorinostat Administered in Combination With Standard Dose of Gemcitabine Plus Either Cisplatin or Carboplatin
DLT = any Common Terminology Criteria for Adverse Events Grade 3/4 drug related non-hematologic toxicity EXCEPT Grade 3 nausea/vomiting responsive to therapy, Grade 3 Fatigue responsive to management, transient electrolyte disorders that were corrected, any Grade 4 drug related hematologic toxicity EXCEPT lymphopenia/neutropenia, unless the neutropenia was febrile and/or was an infection requiring treatment, OR Any Grade 4 neutropenia lasting \>=7 days, failure of absolute neutrophil count or platelets to recover, or any drug-related AE that led to a dose reduction of \>=1 study drugs.
Time frame: every 21 days (every cycle), up to 126 days (6 cycles)
Maximum Tolerated Dose of Vorinostat Administered in Combination With Standard Doses of Gemcitabine Plus Either Cisplatin or Carboplatin in Patients With Advanced Stage Non-Small Cell Lung Cancer Who Have Not Received Chemotherapy for Advanced Disease
Maximum tolerated dose (MTD) was defined as the highest dose level in which fewer than 2 patients among the first 6 enrolled experience a DLT (as defined in Outcome Measure 1) during the first cycle of treatment. The MTD was 400 mg for up to 10 days in 21-day cycles.
Time frame: every 21 days (every cycle), up to 126 days (6 cycles)
Number of Participants With Clinical Adverse Experiences (Safety and Tolerability)
An adverse experience (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience. The AEs could have been any grade from 1 to 5 in severity (mild, moderate, severe, life-threatening, death, respectively).
Time frame: every 21 days (every cycle), up to 126 days (6 cycles)
Number of Participants With Laboratory Adverse Experiences (Safety and Tolerability)
An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience. The AEs could have been any grade from 1 to 5 in severity (mild, moderate, severe, life-threatening, death, respectively).
Time frame: every 21 days (every cycle), up to 126 days (6 cycles)
| Milestone | Vorinostat 300 7/21+ Gemcitabine 1000 + Cisplatin | Vorinostat 300 7/21+ Gemcitabine 1250 + Cisplatin | Vorinostat 400 7/21+ Gemcitabine 1250 + Cisplatin | Vorinostat 400 10/21+ Gemcitabine 1250 + Cisplatin | Vorinostat 400 14/21+ Gemcitabine 1250 + Cisplatin |
|---|---|---|---|---|---|
| Started | 4 | 6 | 17 | 27 | 7 |
| Completed | 1 | 2 | 2 | 5 | 0 |
| Not completed | 3 | 4 | 15 | 22 | 7 |
| Withdrew: Clinical adverse event | 1 | 0 | 1 | 8 | 2 |
| Withdrew: Death | 1 | 0 | 2 | 1 | 1 |
| Withdrew: Progressive disease | 1 | 3 | 8 | 11 | 4 |
| Withdrew: Laboratory adverse event | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 1 | 0 |
DLT = any Common Terminology Criteria for Adverse Events Grade 3/4 drug related non-hematologic toxicity EXCEPT Grade 3 nausea/vomiting responsive to therapy, Grade 3 Fatigue responsive to management, transient electrolyte disorders that were corrected, any Grade 4 drug related hematologic toxicity EXCEPT lymphopenia/neutropenia, unless the neutropenia was febrile and/or was an infection requiring treatment, OR Any Grade 4 neutropenia lasting \>=7 days, failure of absolute neutrophil count or platelets to recover, or any drug-related AE that led to a dose reduction of \>=1 study drugs.
| Participants | Vorinostat 300 7/21+ Gemcitabine 1000 + Cisplatin | Vorinostat 300 7/21+ Gemcitabine 1250 + Cisplatin | Vorinostat 400 7/21+ Gemcitabine 1250 + Cisplatin | Vorinostat 400 10/21+ Gemcitabine 1250 + Cisplatin | Vorinostat 400 14/21+ Gemcitabine 1250 + Cisplatin |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLT) Due to Vorinostat Administered in Combination With Standard Dose of Gemcitabine Plus Either Cisplatin or Carboplatin | 0 | 1 | 0 | 0 | 1 |
An adverse experience (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience. The AEs could have been any grade from 1 to 5 in severity (mild, moderate, severe, life-threatening, death, respectively).
| Participants | Vorinostat 300 7/21+ Gemcitabine 1000 + Cisplatin | Vorinostat 300 7/21+ Gemcitabine 1250 + Cisplatin | Vorinostat 400 7/21+ Gemcitabine 1250 + Cisplatin | Vorinostat 400 10/21+ Gemcitabine 1250 + Cisplatin | Vorinostat 400 14/21+ Gemcitabine 1250 + Cisplatin |
|---|---|---|---|---|---|
| Number of Participants With Clinical Adverse Experiences (Safety and Tolerability) | 4 | 6 | 17 | 27 | 7 |
An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience. The AEs could have been any grade from 1 to 5 in severity (mild, moderate, severe, life-threatening, death, respectively).
| Participants | Vorinostat 300 7/21+ Gemcitabine 1000 + Cisplatin | Vorinostat 300 7/21+ Gemcitabine 1250 + Cisplatin | Vorinostat 400 7/21+ Gemcitabine 1250 + Cisplatin | Vorinostat 400 10/21+ Gemcitabine 1250 + Cisplatin | Vorinostat 400 14/21+ Gemcitabine 1250 + Cisplatin |
|---|---|---|---|---|---|
| Number of Participants With Laboratory Adverse Experiences (Safety and Tolerability) | 2 | 4 | 7 | 13 | 2 |
Maximum tolerated dose (MTD) was defined as the highest dose level in which fewer than 2 patients among the first 6 enrolled experience a DLT (as defined in Outcome Measure 1) during the first cycle of treatment. The MTD was 400 mg for up to 10 days in 21-day cycles.
| mg | All Participants |
|---|---|
| Maximum Tolerated Dose of Vorinostat Administered in Combination With Standard Doses of Gemcitabine Plus Either Cisplatin or Carboplatin in Patients With Advanced Stage Non-Small Cell Lung Cancer Who Have Not Received Chemotherapy for Advanced Disease | 400 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-0683 300 mg x 7d/21d + Gemcitabine 1000 mg/m^2 + Cisplatin | — | 3/4 (75%) | 4/4 (100%) |
| MK-0683 300 mg 7d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin | — | 4/6 (66.7%) | 6/6 (100%) |
| MK-0683 400 mg 7d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin | — | 10/18 (55.6%) | 17/18 (94.4%) |
| MK-0683 400 mg 10d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin | — | 18/27 (66.7%) | 27/27 (100%) |
| MK-0683 400 mg 14d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin | — | 4/7 (57.1%) | 7/7 (100%) |
| Event | MK-0683 300 mg x 7d/21d + Gemcitabine 1000 mg/m^2 + Cisplatin | MK-0683 300 mg 7d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin | MK-0683 400 mg 7d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin | MK-0683 400 mg 10d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin | MK-0683 400 mg 14d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin |
|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 2/4 | 0/6 | 0/18 | 4/27 | 2/7 |
| Chest painGeneral disorders | 0/4 | 2/6 | 0/18 | 0/27 | 0/7 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/4 | 2/6 | 1/18 | 2/27 | 1/7 |
| Venous thrombosisVascular disorders | 0/4 | 2/6 | 0/18 | 0/27 | 1/7 |
| AnaemiaBlood and lymphatic system disorders | 1/4 | 0/6 | 0/18 | 0/27 | 1/7 |
| Disease progressionGeneral disorders | 1/4 | 0/6 | 2/18 | 3/27 | 0/7 |
| PyrexiaGeneral disorders | 1/4 | 0/6 | 3/18 | 0/27 | 0/7 |
| Accidental overdoseInjury, poisoning and procedural complications | 1/4 | 0/6 | 0/18 | 0/27 | 0/7 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/4 | 0/6 | 1/18 | 1/27 | 0/7 |
| Back painMusculoskeletal and connective tissue disorders | 0/4 | 1/6 | 0/18 | 0/27 | 0/7 |
| Event | MK-0683 300 mg x 7d/21d + Gemcitabine 1000 mg/m^2 + Cisplatin | MK-0683 300 mg 7d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin | MK-0683 400 mg 7d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin | MK-0683 400 mg 10d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin | MK-0683 400 mg 14d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 4/4 | 6/6 | 11/18 | 23/27 | 4/7 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/4 | 6/6 | 10/18 | 18/27 | 5/7 |
| AstheniaGeneral disorders | 4/4 | 6/6 | 12/18 | 22/27 | 5/7 |
| NauseaGastrointestinal disorders | 1/4 | 5/6 | 11/18 | 19/27 | 4/7 |
| PyrexiaGeneral disorders | 3/4 | 2/6 | 2/18 | 6/27 | 1/7 |
| NeutropeniaBlood and lymphatic system disorders | 2/4 | 4/6 | 12/18 | 15/27 | 5/7 |
| ConstipationGastrointestinal disorders | 2/4 | 2/6 | 8/18 | 9/27 | 5/7 |
| VomitingGastrointestinal disorders | 1/4 | 4/6 | 7/18 | 13/27 | 5/7 |
| Decreased appetiteMetabolism and nutrition disorders | 2/4 | 2/6 | 8/18 | 16/27 | 5/7 |
| LeukopeniaBlood and lymphatic system disorders | 1/4 | 2/6 | 6/18 | 9/27 | 4/7 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 56.7 ± 9.2 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 17 |
| Male | 44 |
No study locations are listed for this record.
The record gives a start of Mar 2007, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vorinostat · Gemcitabine
Carcinoma, Non-Small-Cell Lung →